Corcept Therapeutics Plummets 50% After FDA Rejects Lead Drug; Class Action Lawsuit Filed

Corcept Therapeutics Incorporated ($CORT) is facing a securities fraud class action lawsuit following a devastating regulatory setback that wiped out half the company's stock value in a single day. On December 31, 2025, the FDA issued a Complete Response Letter rejecting the company's lead drug candidate relacorilant, contradicting prior investor assurances about the likelihood of approval. The stock plummeted 50.4% from $70.20 to $34.80 following the announcement, triggering legal action from shareholders who claim they were misled about the drug's regulatory pathway and approval prospects.

The lawsuit, being managed by law firm Kahn Swick & Foti, LLC, alleges that Corcept made material misrepresentations to investors regarding the company's flagship therapeutic candidate. Investors who purchased shares between October 31, 2024 and December 30, 2025—a 14-month window that encompasses the period leading up to and immediately preceding the FDA's rejection—are eligible to participate in the class action. Lead plaintiff applications must be filed by April 21, 2026, giving shareholders approximately 16 weeks from the rejection date to join the litigation.

Key Details of the Regulatory Rejection and Market Impact

The FDA's Complete Response Letter represents one of the most serious regulatory outcomes a pharmaceutical company can receive, indicating that the agency found the application insufficient to approve the drug in its current form. For Corcept, the rejection of relacorilant is particularly significant because the company had positioned this candidate as a critical growth driver and core part of its pipeline strategy.

The market's reaction was swift and severe:

• Stock decline: 50.4% single-day drop from $70.20 to $34.80
• Eligible claim period: October 31, 2024 through December 30, 2025
• Lead plaintiff deadline: April 21, 2026
• Regulatory outcome: FDA Complete Response Letter (most serious non-approval outcome)

The timing of the rejection on December 31, 2025—New Year's Eve—meant the news hit markets during a period of typically lower trading volume, potentially magnifying the percentage decline. The stock's collapse suggests investors had previously priced in significant probability of FDA approval based on company communications and guidance.

Market Context: Biotech Volatility and Regulatory Risk

The Corcept collapse underscores the inherent volatility and regulatory risk embedded in pharmaceutical development. The biotech sector regularly experiences violent stock swings based on FDA decisions, clinical trial outcomes, and regulatory communications. For specialty pharmaceutical companies like Corcept, which rely on a smaller number of pipeline assets, a single regulatory failure can threaten the entire investment thesis.

The Complete Response Letter, rather than an outright Refusal to File or standard rejection, suggests the FDA has specific deficiencies it identified in Corcept's application rather than fundamental flaws in the drug candidate itself. This could mean the company may have a path to resubmission, though any resubmission would require additional time, data, or clinical work—delaying revenue generation and burning additional capital.

The shareholder lawsuit hinges on the allegation that Corcept provided overly optimistic or misleading representations about the likelihood of FDA approval during the 14-month period in question. The complaint presumably contends that:

• The company represented a higher probability of approval than warranted by available evidence
• Material adverse information about the application's status was not disclosed to investors
• Investor decisions to buy or hold shares were made on the basis of false or misleading statements regarding regulatory prospects

This regulatory environment has become increasingly complex for pharmaceutical companies, which face intense pressure to communicate development progress to investors while avoiding claims that could later be characterized as misleading if regulatory outcomes prove disappointing.

Investor Implications and Litigation Landscape

For shareholders, the implications are multifaceted. Those who purchased during the October 2024 to December 2025 window face both direct losses from the stock price decline and the uncertain outcome of the pending litigation. Even if successful, securities class actions typically recover only a portion of shareholder losses, and the recovery timeline can extend several years.

The case also raises questions about Corcept's credibility with institutional investors and analysts who may have relied on company guidance. The 50% stock decline suggests the market had not fully priced in the risk of an FDA rejection, indicating either insufficient risk disclosure by the company or overly optimistic market expectations.

Beyond Corcept, this case may have spillover effects on how investors view other biotech companies' regulatory communications. Shareholder litigation following disappointing FDA outcomes has become increasingly common, and pharmaceutical companies now face heightened scrutiny regarding the claims they make about development-stage candidates and approval probabilities.

Investors holding Corcept stock should monitor the litigation's progress, company filings regarding the FDA rejection, and any management commentary about potential resubmission strategies. The company's cash position, burn rate, and access to capital will become critical factors in determining whether the company can survive the loss of its lead candidate or whether resubmission efforts are economically viable.

What Happens Next

Corcept Therapeutics now faces a challenging path forward. The company must decide whether to pursue a resubmission to address FDA deficiencies, a decision that will depend on the specific feedback provided in the Complete Response Letter and the company's financial resources. Meanwhile, the securities litigation will proceed on a parallel track, with potential implications for company leadership and corporate governance.

The case serves as a stark reminder of the regulatory and litigation risks inherent in biotech investing, where a single FDA decision can fundamentally alter a company's prospects and shareholder value. For investors considering pharmaceutical and biotech investments, the Corcept situation underscores the importance of maintaining realistic expectations about approval probabilities, scrutinizing management communications carefully, and understanding the company's pipeline depth and financial runway.

Shareholders with questions about the class action or their eligibility to participate can contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC. As the April 21, 2026 lead plaintiff deadline approaches, affected investors should review their transaction history and consider their options under the litigation.